Cat. No.: HY-13902

Berzosertib

(Synonyms: VE-822; VX-970; M6620)

26 Cited Publications

Customer Review

Based on 26 publication(s) in Google Scholar

Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G₂/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer.

For research use only. We do not sell to patients.

Purity: 99.44%
CAS No.: 1232416-25-9
Formula: C₂₄H₂₅N₅O₃S
Molecular Weight:463.55

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Berzosertib Chemical Structure

CAS No.: 1232416-25-9

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (26)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

ATR

0.2 nM (Ki)

ATM

34 nM (Ki)

Caspase-3

All ATM/ATR Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HT-29	IC₅₀	19 nM Compound: 103	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37300915]

In Vitro

Berzosertib (0.031-1 µM; 72 h) reduces cell viability in Cal-27 and FaDu HNSCC cell lines with IC₅₀ values of 0.285 µM and 0.252 µM, respectively^[1].
Berzosertib (0.125-0.5 µM; 24-48 h) inhibits migration in Cal-27 and in FaDu HNSCC cells^[1].
Berzosertib (0.25-0.5 µM; 48 h) induces apoptosis in Cal-27 and FaDu cells^[1].
Berzosertib (48-72 h) inhibits proliferation of A549, NCI-H226, and NCI-H520 cells with IC₅₀ values in the 1-4 μM range^[2].
Berzosertib (40-80 nM; 1 h) enhances radiosensitivity of A549, NCI-H226, and NCI-H520 NSCLC cell lines^[2].
Berzosertib (40 nM; 1 h) inhibits radiation-induced ATR (Thr1989) phosphorylation in A549, NCI-H226, and NCI-H520 NSCLC cell lines without affecting ATM (Ser1981) activation^[2].
Berzosertib (40 nM; 1 h) abrogates the radiation-induced G₂/M cell cycle checkpoint in A549 NSCLC cells, shifting cells into G₁ phase^[2].
Berzosertib (40-80 nM; 1 h) enhances radiation-induced apoptosis in A549 NSCLC cells when combined with 10 Gy, but not 2 Gy, irradiation^[2].
Berzosertib (40 nM; 1 h) inhibits DNA double-strand break repair in A549 cells^[2].
Berzosertib (1 µM; 2 h) impairs irradiation-induced G₂/M checkpoint initiation and maintenance in HCT116 and CT26 cells, promoting mitotic entry after DNA damage^[4].
Berzosertib (1 µM; 2 h) combined with 5 Gy irradiation increases micronuclei formation and cytosolic dsDNA levels in HCT116 and CT26 colorectal cancer cell lines^[4].
Berzosertib (1 µM; 2 h) combined with 5 Gy irradiation robustly activates the canonical cGAS-STING-pTBK1/pIRF3 pathway, and upregulates expression of interferon-stimulated genes CXCL10, CCL5, and IFNB in HCT116, SW480, CT26, and MC38 cells^[4].
Berzosertib (1 µM; 2 h) combined with 5 Gy irradiation inhibits the recruitment of SHP1 to the TRAF6/STING complex in HCT116 cells, enhancing TRAF6-STING interaction^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Cal-27, FaDu cells
Concentration:

0.125; 0.25; 0.5 µM
Incubation Time:

24 h (Cal-27); 48 h (FaDu)
Result:

Reduced Cal-27 cell gap closure to 82% at 0.25 µM and 50% at 0.5 µM at 24 h, compared to 98% in untreated cells.
Reduced FaDu cell gap closure to 24% at 0.25 µM and 0.5 µM at 24 h, compared to 41% in untreated cells.
Significantly inhibited FaDu cell gap closure at 0.5 µM at 48 h.

Cell Viability Assay^[1]

Cell Line:

Cal-27, FaDu cells
Concentration:

0.031; 0.063; 0.125; 0.25; 0.5; 1 µM
Incubation Time:

72 h
Result:

Caused a dose-dependent decrease in cell viability in both cell lines.
Exhibited an IC₅₀ value of 0.285 µM for Cal-27 cells.
Exhibited an IC₅₀ value of 0.252 µM for FaDu cells.

Apoptosis Analysis^[1]

Cell Line:

Cal-27, FaDu cells
Concentration:

0.25 µM (Cal-27); 0.5 µM (FaDu)
Incubation Time:

48 h
Result:

Increased apoptosis levels to 279% of control in Cal-27 cells.
Increased apoptosis levels to 244% of control in FaDu cells.

Western Blot Analysis^[2]

Cell Line:

A549, NCI-H226, and NCI-H520 cells
Concentration:

40 nM
Incubation Time:

1 h
Result:

Did not affect radiation-induced ATM (Ser1981) phosphorylation.
Diminished radiation-induced activation of p-ATR (Thr1989) in all three cell lines even at 24 h post-radiation.

Apoptosis Analysis^[2]

Cell Line:

A549 cells
Concentration:

40; 80 nM
Incubation Time:

1 h
Result:

Showed no increase in apoptosis when combined with 2 Gy radiation.
Caused a significant increase in apoptosis when combined with 10 Gy radiation, compared to radiation alone.

Immunofluorescence^[2]

Cell Line:

A549 cells
Concentration:

40 nM
Incubation Time:

1 h
Result:

Combined with irradiation resulted in a statistically significant increase in the number of γH2AX foci at 8 h and 24 h compared with cells treated with irradiation alone.

Real Time qPCR^[4]

Cell Line:

HCT116, SW480, CT26, MC38
Concentration:

1 µM
Incubation Time:

2 h
Result:

Caused a sharp, time-dependent increase in mRNA levels of CXCL10, CCL5, and IFNB in HCT116 and CT26 cells, with peak expression at 8-12 hours post-irradiation.
Induced significant increases in CXCL10, CCL5, and IFNB gene expressions in SW480 and MC38 cells compared to irradiation alone.

In Vivo

Berzosertib (60 mg/kg; p.o.; daily; 10 days; 1 h before 2 Gy local tumor irradiation) acts synergistically with daily 2 Gy local radiation to delay subcutaneous NSCLC brain metastasis PDX tumor growth in mice^[2].
Berzosertib (60 mg/kg; p.o.; daily; 5 days; 1 h before 2.5 Gy whole brain irradiation) combined with daily 2.5 Gy whole brain irradiation significantly improves median overall survival and reduces intracranial tumor growth in mouse NSCLC brain metastasis xenograft model^[2].
Berzosertib (60 mg/kg; i.g.; 2 h before Gy IR, then daily for 3 days) produces antitumor efficacy in mouse MC38 and CT26 models, when combined with 5 Gy irradiation and anti-PD-L1^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Hsd:athymic Nude-Foxn1 mice (6-8-week-old) subcutaneously implantated with UW-lung-16 and UW-lung-18^[2]
Dosage:

60 mg/kg
Administration:

p.o.; daily; 10 days; 1 h before 2 Gy local tumor irradiation
Result:

Delayed growth of UW-lung-16 and UW-lung-18 tumors.
Reduced estimated tumor growth curve slope for UW-lung-16 tumors significantly lower than alone, with a synergistic effect and dose enhancement factor (DEF) of 1.8.
Reduced estimated tumor growth curve slope for UW-lung-18 tumors significantly lower than alone, with a synergistic effect and DEF of 1.4.
Inhibited phospho-Chk1 (Ser345) alone and combined with irradiation.
Increased cleaved caspase-3 in the combination group.
Induced significantly more γH2AX foci in the combination group compared to other groups.

Animal Model:

Athymic nude mice intracranial implantation of luciferase-transfected UW-Lung-16 cells^[2]
Dosage:

60 mg/kg
Administration:

p.o.; daily; 5 days; 1 h before 2.5 Gy whole brain irradiation
Result:

Reduced bioluminescence total flux significantly by days 32 and 40 post-implant compared to radiation alone.
Improved median overall survival to 95 days, compared to 67 days in the radiation alone group.
Showed no significant difference in body weight between groups during or 40 days post-treatment.

Animal Model:

Balb/C mice (female, 5-6 weeks old) subcutaneously injected with CT26 cells^[4]
Dosage:

60 mg/kg
Administration:

i.g.; 2 h before Gy IR, then daily for 3 days
Result:

Delayed tumor growth more effectively than dual or monotherapy regimens.
Extended mouse survival compared to other treatment groups.
Increased CD3⁺ and CD8⁺ tumor-infiltrating lymphocyte counts.
Elevated levels of CD11c⁺ MHC-II⁺ dendritic cells and CD11c⁺ CD8⁺ tumor-infiltrating dendritic cells.
Increased CD86 maturation marker mean fluorescence intensity.
Activated the canonical cGAS-STING-pTBK1/pIRF3 axis.
Activated the non-canonical STING-p65 axis.
Upregulated mRNA expression of innate immune-related genes Cxcl10, Ccl5, and Ifnb.
Decreased SHP1 mRNA levels and SHP1 interaction with TRAF6/STING via promoting SHP1 SUMOylation at lysine 127.

Animal Model:

C57/B6J mice (female, 5-6 weeks old) subcutaneously injected with MC38 cells^[4]
Dosage:

60 mg/kg
Administration:

i.g.; 2 h before Gy IR, then daily for 3 days
Result:

complete tumor regression in some mice.
Extended mouse survival compared to other treatment groups.
Reduced tumor burden (as measured by bioluminescence total flux).
Decreased Ki67-positive proliferating cells.
Increased TUNEL-positive apoptotic cells.
Increased CD3⁺ and CD8⁺ tumor-infiltrating lymphocyte counts.
Elevated levels of CD11c⁺ MHC-II⁺ dendritic cells and CD11c⁺ CD8⁺ tumor-infiltrating dendritic cells.
Increased CD86 maturation marker mean fluorescence intensity.
Activated the canonical cGAS-STING-pTBK1/pIRF3 axis.
Activated the non-canonical STING-p65 axis.
Upregulated mRNA expression of innate immune-related genes Cxcl10, Ccl5, and Ifnb.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1232416-25-9
Appearance Solid
Molecular Weight 463.55
Formula C₂₄H₂₅N₅O₃S
Color Light yellow to yellow
SMILES

NC1=NC=C(C2=CC=C(S(=O)(C(C)C)=O)C=C2)N=C1C3=CC(C4=CC=C(CNC)C=C4)=NO3
Synonyms

VE-822; VX-970; M6620
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (26)

All In Vivo Efficacy StudyFlow CytometryCell Proliferation/Viability AssayIFWB

Sort by:

Journal Impact Factor

Cancer Commun (Lond)

Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. [Abstract]

2023 Apr;43(4):435-454. PMID: 36855844

Berzosertib purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2023 Apr;43(4):435-454. [Abstract]

Berzosertib (60 mg/kg) was administered by gavage 2 h before IR and consecutively for the next three days. Representative IHC images of CD3 staining of MC38 tumors were shown.

Berzosertib purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2023 Apr;43(4):435-454. [Abstract]

Berzosertib (60 mg/kg) was administered by gavage 2 h before IR and consecutively for the next three days. Representative flow cytometry images and quantitative analysis of TILs in CT26 tumors were obtained.

Berzosertib purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2023 Apr;43(4):435-454. [Abstract]

Berzosertib (0–2 μM; 24 h). Cell viability assay of multiple CRC cell lines treated with ATRi and IR + ATRi was performed.

Berzosertib purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2023 Apr;43(4):435-454. [Abstract]

Berzosertib (1 μM). Cell cycle distribution analysis of HCT116 and CT26 cells treated with IR and IR + ATRi. Representative flow cytometry images of phospho-histone H3+ cells in HCT116 and CT26 cells were shown.

Berzosertib purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2023 Apr;43(4):435-454. [Abstract]

Berzosertib (1 μM; 14 h). IF images of dsDNA and cGAS staining in HCT116 cells were shown.

Berzosertib purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2023 Apr;43(4):435-454. [Abstract]

Berzosertib (1 μM; 14 h) was used. Immunoblotting of the key proteins from the canonical cGAS-STING axis in multiple CRC cell lines was performed.
Nat Commun

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. [Abstract]

2019 Jul 2;10(1):2910. PMID: 31266951
Sci Transl Med

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. [Abstract]

2020 Feb 19;12(531):eaax2625. PMID: 32075943
Clin Cancer Res

Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. [Abstract]

2022 Jun 1;28(11):2397-2408. PMID: 35325095
Cancer Lett

2026 Feb 4;642:218300.
Cancer Lett

Targeting ATR signaling in sarcoma with homologous recombination deficiency. [Abstract]

2026 Apr 1:642:218300. PMID: 41651400
Cell Death Dis

KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma. [Abstract]

2024 Dec 6;15(12):882. PMID: 39638799
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
NPJ Breast Cancer

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. [Abstract]

2025 Dec 3;11(1):135. PMID: 41339342
Biomed Pharmacother

Dihydroartemisinin enhances NKG2D CAR-T cell therapy against solid tumors by inducing NKG2D ligands and remodeling the tumor microenvironment. [Abstract]

2026 Feb:195:118974. PMID: 41529511
Cell Rep

MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity. [Abstract]

2021 Mar 2;34(9):108808. PMID: 33657372
Oncogenesis

STAG2 expression imparts distinct therapeutic vulnerabilities in muscle-invasive bladder cancer cells. [Abstract]

2025 Mar 1;14(1):4. PMID: 40025053
Eur J Med Chem

New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. [Abstract]

2017 Feb 15:127:691-702. PMID: 27823879

Berzosertib purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2017 Feb 15:127:691-702. [Abstract]

Relative cell viability (%) in MDCK CAIX^- and CAIX⁺ cells exposed to ATR inhibitors (VE-821 and VE-822) or the CAIXi conjugated derivatives in combination with radiation during normoxia (21% O₂) and anoxia (≤0.02% O₂). Normoxic cells are irradiated with 2 Gy and anoxic cells with 4 Gy to induce similar effects on cell viability.
Cancer Immunol Immunother

Combination of ataxia telangiectasia and Rad3-related inhibition with ablative radiotherapy remodels the tumor microenvironment and enhances immunotherapy response in lung cancer. [Abstract]

2024 Nov 2;74(1):8. PMID: 39487895
Cell Oncol (Dordr)

Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy. [Abstract]

2022 Dec;45(6):1401-1419. PMID: 36269546
Mol Cancer Res

Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2. [Abstract]

2020 Jan;18(1):91-104. PMID: 31649026
Mol Oncol

Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer. [Abstract]

2025 Jul 13. PMID: 40652528
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
J Biol Chem

The E3 ligase β-TRCP1 earmarks OTUD3 for destruction to fine-tune cGAS activation. [Abstract]

2026 Jun;302(6):111461. PMID: 41999888
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Anticancer Res

Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines. [Abstract]

2019 Jul;39(7):3553-3563. PMID: 31262879
Patent

US20240285616A1
Research Square Preprint

2024 Nov 06.
Patent

US20240285616A1.
bioRxiv

2024 Mar 28.
University of London

2021 Sep.

Solvent & Solubility

In Vitro:

DMSO : 16.67 mg/mL (35.96 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1573 mL

10.7863 mL

21.5726 mL

5 mM

0.4315 mL

2.1573 mL

4.3145 mL

10 mM

0.2157 mL

1.0786 mL

2.1573 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (3.60 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Schnoell J, et al. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines. Invest New Drugs. 2023;41(6):842-850. [Content Brief]

[2]. Baschnagel AM, et al. ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts. Mol Cancer Ther. 2021;20(11):2129-2139. [Content Brief]

[3]. Fokas E, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012;3(12):e441. Published 2012 Dec 6. [Content Brief]

[4]. Liu C, et al. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. Cancer Commun (Lond). 2023;43(4):435-454. [Content Brief]

[5]. Gorainow N, et al. Berzosertib enhances the sensitivity of pediatric diffuse midline glioma H3K27-altered cells to radiotherapy. Cell Death Dis. 2026;17(1):331. Published 2026 Mar 20. [Content Brief]

[6]. Kurmasheva RT, et al. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2018;65(2):10.1002/pbc.26825. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1573 mL	10.7863 mL	21.5726 mL	53.9316 mL
	5 mM	0.4315 mL	2.1573 mL	4.3145 mL	10.7863 mL
	10 mM	0.2157 mL	1.0786 mL	2.1573 mL	5.3932 mL
	15 mM	0.1438 mL	0.7191 mL	1.4382 mL	3.5954 mL
	20 mM	0.1079 mL	0.5393 mL	1.0786 mL	2.6966 mL
	25 mM	0.0863 mL	0.4315 mL	0.8629 mL	2.1573 mL
	30 mM	0.0719 mL	0.3595 mL	0.7191 mL	1.7977 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Berzosertib

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Anti-Colorectal Cancer Compound Library

Cancer Stem Cells Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Immunopotentiator Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) Berzosertib

All ATM/ATR Isoforms

All Caspase Isoforms

Biological Activity

Chemical Information

Publications (26)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Berzosertib Related Classifications

Cat. No.: HY-13902